Validation of new medication use algorithms as proxies for worsening disease activity in patients with juvenile idiopathic arthritis
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5803 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Kyoko Saito und 8 weiteren Autor:innen. Beteiligte Einrichtung: Brown University, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Arthritis, Juvenile, Algorithms, Antirheumatic Agents, Electronic Health Records. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Purpose
To facilitate claims‐based research on populations with juvenile idiopathic arthritis (JIA), we sought to validate an algorithm of new medication use as a proxy for worsening JIA disease activity.
Methods
Using electronic health record data from three pediatric centers, we defined new JIA medication use as (re)initiation of disease‐modifying antirheumatic drugs or glucocorticoids (oral or intra‐articular). Data were collected from 201 randomly selected subjects with (101) or without (100) new medication use. We assessed the positive predictive value (PPV) and negative predictive value (NPV) based on a reference standard of documented worsening of JIA disease activity. The algorithm was refined to optimize test characteristics.
Results
Overall, the medication‐based algorithm had suboptimal performance in representing worsening JIA disease activity (PPV 69.3%, NPV 77.1%). However, algorithm performance improved for definitions specifying longer times after JIA diagnosis (≥1‐year post‐diagnosis: PPV 82.9%, NPV 80.0%) or after initiation of prior JIA treatment (≥1‐year post‐treatment: PPV 89.7%, NPV 80.0%).
Conclusion
An algorithm for new JIA medication use appears to be a reasonable proxy for worsening JIA disease activity, particularly when specifying new use ≥1 year since initiating a prior JIA medication. This algorithm will be valuable for conducting research on JIA populations within administrative claims databases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brown University, Providence, Rhode Island, USA.
- St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, USA.
- Nemours Children's Hospital, Wilmington, Delaware, USA.
- Arkansas Children's Hospital, Little Rock, Arkansas, USA.
- Childhood Arthritis & Rheumatology Research Alliance, Washington, DC, USA.
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Daniel B Horton
Förderung
- NCATS NIH HHS
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Center for Advancing Translational Sciences
Zitieren
APA
Saito, K., Gabbeta, A., Mulvihill, E., Al-Jaberi, L., Beukelman, T., Lewis, J. D., Rose, C. D., Strom, B. L., & Horton, D. B. (2024). Validation of new medication use algorithms as proxies for worsening disease activity in patients with juvenile idiopathic arthritis. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5803
Vancouver
Saito K, Gabbeta A, Mulvihill E, Al-Jaberi L, Beukelman T, Lewis JD, et al. Validation of new medication use algorithms as proxies for worsening disease activity in patients with juvenile idiopathic arthritis. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5803
BibTeX
@article{Saito2024,
author = {Saito, Kyoko and Gabbeta, Avinash and Mulvihill, Evan and Al-Jaberi, Lina and Beukelman, Timothy and Lewis, James D and Rose, Carlos D and Strom, Brian L and Horton, Daniel B},
title = {Validation of new medication use algorithms as proxies for worsening disease activity in patients with juvenile idiopathic arthritis},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5803}
}
EUVIMED